| <strong>For patients with RMD, continuing immunosuppressive medications around the time of other (non‐influenza) non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550                    |
| <strong>Timing vaccinations in patients receiving rituximab to maximize vaccine efficacy</strong>    | <strong>Low</strong>                                          | PICO 17. Should patients with RMD who are taking rituximab time non–live attenuated vaccine administration relative to the next dose of medication? | 927–930                  |